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Abstract: Encapsulation of nonsteroidal or non-steroidal anti-inflammatory drugs (NSAID) in nanocarrier systems aims 
to enhance bioavailability and to decrease toxicity of these drugs and thus improve the efficacy of treatments. With this 
aim two types of nanoparticles were prepared and compared: lipid nanoparticles, made of cetyl palmitate and Miglyol 
812 which were uncoated or coated with chitosan; or polymeric nanoparticles, made of poly (DL-lactic-co-glycolic acid) 
(PLGA) for which different emulsion stabilizers were also tested (poly (vinyl alcohol) (PVA), and Pluronic F68). 
Nanoparticles were characterized for drug content and for particle size, charge and morphology. The lipid matrix was 
analyzed regarding its crystallinity by differential scanning calorimetry (DSC). The size of the nanoparticles was 
measured by dynamic light scattering (DLS) which indicated a unimodal particle size distribution in all systems. 
Nanoparticles’ stability was confirmed by their highly negative surface charge in the case of polymeric and uncoated lipid 
nanoparticles, as analyzed by zeta potential measurements using electrophoretic light scattering (ELS). Lipid chitosan 
coated nanoparticles have also shown to be stable presenting highly positive surface charge. Results have further 
demonstrated that indomethacin is highly encapsulated regardless the type of particles. Morphological analysis by 
scanning electron microscopy has shown that the nanoparticles were smooth and spherical. 
The results gathered within the current study point to the conclusion that the proposed formulations provide 
nanoparticles of satisfactory quality to encapsulate indomethacin, which might be used to improve bioavailability of other 
NSAID in the treatment of inflammation. 
Keywords: NSAID, PLGA nanoparticles, nanostructured lipid carriers (NLC), encapsulation efficiency, dynamic and 
electrophoretic light scattering (DLS and ELS), differential scanning calorimetry (DSC), electron scanning 
microscopy (SEM). 
INTRODUCTION 
Biocompatible, biodegradable colloidal systems for 
drug delivery are generally composed of either lipids or 
polymers [1] as both materials have several 
advantages. Polymeric colloids such as polymeric 
nanoparticles (NP) are easier to produce, are capable 
of delivering both hydrophilic and lipophilic drugs, and 
have monodisperse size distribution and morphology 
[1]. Lipid colloids are inherently more efficient systems 
for encapsulation of the highly lipophilic compounds 
(which is the case of the majority of drugs), and are 
less prone to cause toxicity or immune responses [1]. 
Moreover the encapsulation of drugs in lipid colloidal 
systems will favor drug solubilization and will further 
enhance the oral absorption of drugs [2, 3] due to the 
fact that lipids and pharmaceutical drugs are co-
absorbed in the gut to the lymphatic circulation [2] and 
this simultaneous absorption increases the drug 
bioavailability by avoiding the first-pass metabolism. In 
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comparison to the most successful lipid colloidal 
nanocarrier systems – liposomes; lipid nanoparticles 
are lipid colloidal systems that demonstrate similar 
efficiency regarding the increase of therapeutic benefits 
with comparable minimization of the toxic and harmful 
effects to the patient [1]. Additionally, both lipid and 
polymeric nanoparticles present advantages relatively 
to liposomes, such as stability, both in biological fluids 
and during storage phase; lower price of production; 
and increasing possibility of developing scale-up 
preparation procedures [2, 4, 5]. 
Non-steroidal anti-inflammatory drugs (NSAID) 
emerged as a highly effective class of drugs against 
various arthritic conditions and post-operative 
inflammation and constitute one of the most prescribed 
groups of therapeutics worldwide due to their anti-
inflammatory, anti-stroke, antipyretic and analgesic 
actions [6-9]. However, several patients that were 
medicated with these drugs have been hospitalized 
due to severe gastrointestinal (GI) lesions [9, 10]. 
These adverse side effects greatly restrain the amount 
of the pharmaceutical drug administered and therefore 
limit the therapeutic usage of NSAID [9]. The 
mechanisms of gastric toxicity of NSAID are complex 
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and mucosal damage can also be related to a local 
acid effect of the dissolved drug in the gastric 
membrane [11]. Hence, there is a great potential in the 
incorporation of NSAID into controlled release dosage 
forms which may minimize local GI aggressive side 
effects for the patient [9]. Indomethacin is one of the 
most potent NSAID, although nowadays its use is 
almost restricted to dermal formulations since the oral 
formulations present great gastric toxicity.  
Despite of numerous studies attempting the 
encapsulation of indomethacin [1, 12-34] there is no 
clear evidence regarding the choice of the 
nanoparticles matrix and/or stabilizers for attaining the 
best nanocarriers. Regardless of the great potentiality 
of lipid nanoparticles for the encapsulation of 
indomethacin fewer studies exist, to our knowledge, 
addressing the use of lipid nanoparticles as carriers of 
this NSAID (Table 1). Among the reported polymeric 
NP, Poly (DL-lactic-co-glycolic acid) (PLGA) stabilized 
with polyvinyl alcohol (PVA) is a widely chosen 
composition that presented variable encapsulation 
potential for indomethacin and different range of 
particle sizes (Table 2). 
Taking in consideration the previous studies of 
indomethacin encapsulation (Tables 1 and 2) we 
propose herein the encapsulation of indomethacin into 
two types of nanodelivery systems: polymeric 
nanoparticles of Poly (DL-lactic-co-glycolic acid) 
(PLGA-NP) and nanostructured lipid carriers (NLC). 
The aim is to make use of the above mentioned 
advantages of polymeric and lipid nanoparticles as 
nanocarriers for hydrophobic drugs, as these 
nanocarriers may be a promising strategy to reduce the 
contact of the drug within the GI mucosa [5, 35-38]. 
The chosen PLGA matrix was based on the physical 
and chemical properties of this bioabsorbable polymer, 
which is non-toxic and biodegradable and therefore 
useful in several biomedical applications [39-42]. Two 
stabilizers (PVA and Pluronic 68) will be studied 
regarding their effect in the final polymeric 
nanoparticles physical-chemical properties, as this 
aspect has been mainly underestimated in the previous 
reported studies of Table 2. Besides aiming the 
improvement of indomethacin absorption and 
protection against topical gastric irritancy, NLC were 
also chosen for indomethacin encapsulation for being 
composed of spatially very different lipids, with an 
increased number of imperfections that leads to an 
increased loading capacity for pharmaceutical drugs 
[43], comparing to other lipid nanoparticles, such as 
solid lipid nanoparticles (SLN) [2, 4, 44]. Only two 
studies have been proposed for the encapsulation of 
indomethacin in NLC (Table 1) and one was neither 
successful in the encapsulation nor in the size of the 
NP achieved. Therefore there is still room for 
improvement in the preparation of NLC for 
indomethacin encapsulation. The monoester cetyl 
palmitate and the medium chain triglyceride Miglyol 
812 were chosen to be part of the lipid matrix due to 
their biocompatibility and biodegradability and excellent 
physical properties [44, 45]. NLC were further coated 
with chitosan (CS) for its biocompatibility, 
biodegradability and ability to modify reversibly the tight 
Table 1: Reported Lipid Nanoparticles Used to Encapsulate Indomethacin 
COMPOSITION % ENCAPSULATION 
%DRUG LOADING 
SIZE ZETA 
POTENTIAL 
ADMINISTRATION 
ROUTE 
REFERENCE 
SLN: Compritol 888 ATO 
NLC: Compritol 888 ATO+ 
Miglyol 812 
SURFACTANT: Lutrol F68 
EE=76% (SLN)  
DL=1% w/w 
EE=83% (NLC) 
DL = 1.12% w/w 
80-270 nm 
(NLC) 
102-215 nm 
(SLN) 
ND ND [14] 
NLC: Precirol+Miglyol 812 
SURFACTANT: Polysorbate 
80 
Not successfull 
 
0.5-20 ?m ND parenteral 
iv 
[22] 
SLN: tripalmitin, tristearin or 
Gelucire 50/13 
SURFACTANT:soy lecithin 
EE=80–90%  
DL =10-15% w/w 
20-60 nm; 200 
nm 
ND pulmonary [28]  
SLM: Phospholipon 90H + 
Softisan 154 
SURFACTANT: Tween 80 
EE=50-96% 
DL=3-5 % w/w 
0.58-21 ?m ND oral [29]  
Abbreviations: SLN=solid lipid nanoparticles; NLC=nanostructured lipid carriers; SLM=solid lipid microparticles. EE=Encapsulation efficiency; DL=Drug loading; 
ND=Not defined. 
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junctions between the cells, which makes this intestinal 
mucoadhesive hydrophilic polysaccharide a frequent 
component in nanocarriers for drugs intended to be 
orally administrated [46-48]. CS hydrophilic coating of 
nanoparticles was intended to improve the stability of 
the colloidal systems in contact with the mucosa 
environment and to favor the interaction with epithelia 
in a similar way as other colloidal systems with CS that 
have already been developed [48–52,63]. Additionally, 
none of the previous studies reported on Table 1 has 
used chitosan coating, despite its potentiality for oral 
delivery. 
In summary, with this study we aim unveiling the 
preparation, characterization and comparison (size, 
morphology, surface potential and encapsulation 
efficiency/drug loading efficiency) of four biocompatible 
nanoparticles (polymeric PLGA nanoparticles stabilized 
with PVA or Pluronic and lipidic NLC uncoated or 
coated with CS) with the final goal of providing the best 
options to encapsulate indomethacin and other NSAID, 
hence allowing the future development of more 
tolerable drugs, diminishing the undesirable GI side-
effects. 
2. MATERIALS AND METHODS 
2.1. Materials 
Poly (DL-lactic-co-glycolic acid) (PLGA) with an 
average molecular weight of 66-107 kDa and a 
copolymer ratio of DL- lactide to glycolide ratio of 
75:25; indomethacin; the solvent dichloromethane; the 
emulsion stabilizers: polyvinyl alcohol (PVA) with an 
average molecular weight of 30-70 kDa and 
hydrolyzation degree of 98–99%, pluronic F68 and 
chitosan of low molecular weight (Mw = 50 kDa) were 
all obtained from Sigma Aldrich (St Louis, MO). Cetyl 
palmitate was purchased to Sigma Aldrich (St Louis, 
MO) and Miglyol-812 was purchased from Acofarma 
(Spain). Polysorbate 60 (Tween 60) was obtained from 
Merck (Germany). 
All chemicals and solvents were of analytical grade, 
and were used without further purification. Aqueous 
solutions were prepared with double-deionized water 
(conductivity less than 0.1 μS cm-1). 
2.2. Methods 
2.2.1. Optimization of Preparation Methods  
The process of ultra-homogenization subjects the 
sample to high shear forces that cause repeated 
cavitations in the polymeric/lipid matrix resulting in a 
reduction of vesicle size. Sonication provides a 
rearrangement of the initial multilamellar organization 
into smaller nanoparticles. The ultra-homogenization 
and sonication times were optimized and combined on 
the basis of the vesicle size obtained by dynamic light 
scattering measurements (Malvern Mastersizer, 
Malvern Co., Worcestershire, UK). The times were 
Table 2: Reported Polymeric PLGA Nanoparticles (PLGA-NP) Containing PVA as Stabilizer Used to Encapsulate 
Indomethacin 
COMPOSITION 
% ENCAPSULATION 
%DRUG LOADING 
SIZE 
ZETA 
POTENTIAL 
ADMINISTRATION 
ROUTE 
REFERENCE 
POLYMER: PLGA (50/50) 
STABILIZER: PEG+PVA 
EE=95 % 
DL= ND 
46.6±3.5 ?m ND parenteral [30] 
POLYMER:PLGA (50/50) 
STABILIZER:PVA 
EE=14% 
DL=2.8% w/w 
1.65 -2.35 ?m ND ND [31] 
POLYMER:PLGA (50/50) 
STABILIZER:PVA 
EE=62-100% 
DL=ND 
6-87 ?m ND ND [15] 
POLYMER:PLGA (50/50) 
STABILIZER:PVA 
EE=65.2 % 
DL=6.52% w/w 
0.68-1 ?m ND ND [32]  
POLYMER:PLGA (75/25) 
STABILIZER:PVA 
EE=ND 
DL=3.93% w/w 
102 ± 2.59 nm -2.12±0.31 mV transdermal [33] 
POLYMER:PLGA (50/50) 
STABILIZER:CAPTEX+PVA 
EE=33% 
DL=3% w/w 
189±4.7 nm -17.4±2.2 mV ND [1] 
POLYMER:PLGA (75/25) 
STABILIZER:PVA 
EE=36.4% 
DL=4.25% w/w 
102 ±1.4 nm -0.15±0.05 mV ND [34] 
Abbreviations: PLGA= Poly (DL-lactic-co-glycolic acid); PVA= polyvinyl alcohol; EE=Encapsulation efficiency; DL=Drug loading, ND=Not defined. 
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selected according to the production of nanoparticles of 
optimal size with low polydispersity index (PDI).  
2.2.2. Preparation of Polymeric Nanoparticles  
PLGA-NP were prepared according to a modified 
emulsion-solvent diffusion technique. Briefly, 50 mg of 
PLGA polymer and suitable quantity of indomethacin 
were accurately weighed and dissolved in 5 mL of 
dichloromethane. The organic phase was added 
dropwise into 15 mL of the aqueous phase (double-
deionized water) containing the emulsion stabilizer 
(Pluronic F68 25% (w/v) or PVA 0.5% (w/v)) while 
stirring in vortex (see in Table 3 the composition of the 
nanoparticles).  
The resulting mixture (organic phase containing 
PLGA and indomethacin + aqueous phase containing 
the stabilizer) turned milky instantaneously due to 
immediate polymer precipitation. The homogeneity of 
the emulsion obtained was further improved by two 
cycles of 40 seconds in an ultra-homogeneitor 
(POLYTRON®, PT 2500 E), followed by 3 minutes of 
sonication (Qsonica Misonix S-4000) operating at 70% 
amplitude intensity. After this procedure, 
nanoemulsions were stirred magnetically at room 
temperature during 3 hours which allowed a complete 
evaporation of the organic solvent. Drug free 
nanoparticles were prepared according to the same 
procedure, but without adding indomethacin (Table 3).  
The nanoparticles obtained dispersed in an 
aqueous media were passed through 0.8 ?m filter 
(Millex-syringe filter unit, Millipore) to remove 
aggregates and were stored in hermetically sealed 
containers at 25 °C before posterior analyses. The 
schematic structure of the PLGA-NP prepared is 
presented in Figure 1. 
2.2.3. Preparation of Chitosan Coated and 
Uncoated Lipid Nanoparticles  
Lipid nanoparticles were prepared according to a 
sonication based method. Cetyl palmitate, miglyol-812, 
polysorbate 60 and drug were weighed in appropriate 
quantities and warmed up to 70 °C (see in Table 3 the 
composition of the nanoparticles). Double-deionized 
water was warmed up to the same temperature and 
added to the lipid mixture (added up to 5 g). The 
resultant lipid-water emulsion was homogenized in 
Ultra-homogeneitor during 40 seconds in order to 
obtain a microemulsion by ultrasonic waves. Then, the 
emulsion was sonicated during 3 minutes and the 
resultant nanoemulsion was cooled down to room 
temperature. For the preparation of chitosan (CS) 
coated lipid nanoparticles, 2.5 mL of CS solution 1% 
(w/v) (in 1% of acetic acid) was slowly added to 2.5 g of 
the previously prepared nanoformulation (Table 3) 
under magnetic stirring. The mixture was stirred during 
1 hour. The obtained lipid nanoparticles uncoated 
(NLC1 and NLC2) and CS coated (NLC3 and NLC4) 
were stored in hermetically sealed containers at 25 °C 
before posterior analyses. The schematic structure of 
the PLGA-NP prepared is presented in Figure 2. 
2.2.4. Nanoparticles Characterization 
2.2.4.1. Determination of Encapsulation Efficiency and 
Loading Efficiency  
The formulations were centrifuged (Eppendorf, 
Centrifuge 5418R) through centrifugal filter units 
(Amicon Ultra-4, 10 kDa, Millipore) at 4300 rpm 
(3300?g) at 25 °C for 5 minutes or until complete 
separation between the nanoparticles (pellet retained in 
the filter unit) and the aqueous phase (supernatant). 
The supernatant containing the dissolved free drug was 
analyzed in a Shimadzu UV-3101PC UV/VIS 
Table 3: Composition of the Developed Polymeric PLGA Nanoparticles (PLGA-NP) and Nanostructured Lipid Carriers 
(NLC) 
Formulations Drug: Polymeric matrix (mg/g) PLGA (mg) PVA (mL) Pluronic F-68 (mL) 
PLGA-NP1 0 50 15 0 
PLGA-NP2 35 50 15 0 
PLGA-NP3 0 50 0 15 
PLGA-NP4 35 50 0 15 
Formulations Drug: Lipid matrix (mg/g) Cetyl palmitate (mg) Miglyol-812 (mg) Polysorbate 60 (mg) 
NLC1 and 3 0 225 25 100 
NLC2 and 4 35 213.75 23.75 100 
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Figure 1: Schematic illustration of the Poly (DL-lactic-co-glycolic acid) (PLGA) nanoparticles with different emulsion stabilizers: 
polyvinyl alcohol (PVA) (PLGA-NP1 and PLGA-NP2) and Pluronic F68 (PLGA-NP3 and PLGA-NP4) unloaded (PLGA-NP1 and 
PLGA-NP3) or loaded with indomethacin (PLGA-NP2 and PLGA-NP4).  
 
 
Figure 2: Schematic illustration of nanostructured lipid carriers (NLC) composed of a core of solid lipid (cetyl palmitate) and 
liquid lipid (Miglyol-812) with a surfactant stabilizer (Polysorbate 60) naked (NLC1 and NLC2) or covered with chitosan (NLC3 
and NLC4) unloaded (NLC1 and NLC3) or loaded with indomethacin (NLC2 and NLC4). Comparison with solid lipid 
nanoparticles (SLN) composed only by solid lipids and surfactant stabilizer. 
Spectrometer. Spectra were taken in the range of 230-
350 nm. UV spectra of the nanoparticles without the 
drug incorporated were also analyzed to establish the 
absorbance interference. Considering the initial 
concentration of drug used in the formulation and 
subtracting the free drug concentration present in the 
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supernatant, it is possible to obtain the concentration of 
drug that was incorporated in the PLGA-NP and in the 
NLC. The encapsulation efficiency (EE) and loading 
efficiency was calculated by the equations: 
Encapsulation Efficiency (%) = 
[Drug incorporated in NP]
[Drug used in formulation]
?100  
             (1) 
Loading Efficiency (%) = 
Amount of Drug incorporated in NP
Amount of lipid or polymer in formulation
?100   
              (2) 
2.2.4.2. Nanoparticles Size and Surface Charge 
Nanoparticles size distribution and surface charge 
of the nanoparticles were determined at 25 °C by 
dynamic light scattering (DLS) and electrophoretic light 
scattering (ELS), using a Zetasizer Nano ZS laser 
scattering device (Malvern Instruments Ltd., Malvern, 
UK). The nanoparticles’ size distribution allows 
monitoring the nanoparticle preparation method and 
verifying its time dependent stability regarding the 
tendency for aggregation and sedimentation. For each 
sample, the mean diameter ± standard deviation of at 
least three determinations was calculated applying 
multimodal analysis to the Nanoparticles’ size 
distribution by intensity. Surface charge of the 
nanoparticles is presented as zeta potential values 
from at least three independent determinations. 
2.2.4.3. Nanoparticles Morphology 
Morphological evaluation of the nanoparticles was 
performed using Scanning Electron Microscopy (SEM). 
For SEM analysis, the samples were mounted on 
conductive carbon adhesive attached to aluminum 
stubs. The samples were then coated with platinum 
under vacuum in a sputter coater and analyzed with a 
FEI Quanta 400 FEG scanning electron microscope. 
2.2.4.4. Physical State and Polymorphism of Lipid 
Nanoparticles  
Thermal behavior of lipids and its compatibility with 
other formulation ingredients was estimated using 
differential scanning calorimeter (NETZSCH DSC 
200F3-240-20-427-L, USA). The samples were 
hermetically sealed in aluminum pans and heated at a 
constant rate of 5°C/min over a temperature range of 
25-85°C. An inert atmosphere was maintained by 
purging with nitrogen at a flow rate of 60 mL/min. DSC 
analyses were performed on bulk lipids and NLC. The 
degree of crystallinity or recrystallization index (RI) was 
determined by the following equation (3): 
RI (%) = 
Enthalpy NLC (J/g)
Enthalpy bulk material (J/g) ? lipid phase (%) ?100   
             (3) 
2.2.4.5. Drug Release Studies 
The release studies were carried out using the 
vertical dialysis bags of cellulose membrane (Frilabo, 
Portugal) with a cut off value of 12-14 kDa. Prior to use, 
the membrane was hydrated in purified water for 12 h. 
The final concentration of the drug was always lower 
than 10% (w/w) of its solubility in the receptor medium, 
so that sink conditions could be assumed. 5 g of 
formulations was placed in the donor compartment 
after the receptor compartment was filled with 300 mL 
of receptor medium (pH 7.45). The temperature was 
kept as 37°C and the receptor medium was stirred with 
the help of magnetic stirrer at 100 rpm. Samples of 2 
mL were withdrawn periodically until 24 hrs, replacing 
the samples with the same amount of volume of 
receptor medium kept at the same temperature. The 
amount of released drug was measured by UV analysis 
at 320 nm.  
3. RESULTS AND DISCUSSION 
3.1. Size and Surface Charge of the Nanoparticles 
The mean particle sizes; the polydispersity and zeta 
potential values of PLGA-NP and NLC loaded with 
indomethacin are shown in Figures 3 and 4 
respectively. 
Since PLGA-NP are formed from the emulsion 
droplets after organic solvent diffusion, their size is 
dependent on the stability of the emulsion droplets, 
which collide and coalesce. Ultimately, the size of the 
nanoparticles is dependent upon the type of emulsion 
stabilizer used. When the stabilizer remains at the 
liquid–liquid interface during the diffusion process, and 
if its protective effect is adequate, nanoparticles will 
form [54]. The PLGA-NP produced within this work 
contained non-ionic stabilizer systems (PVA and 
Pluronic F68), where particles are stabilized by steric 
hindrance. Small particle sizes obtained for both types 
of stabilizer systems (sizes ranged between 94-135 
nm, see Figure 3) can be attributed to both the 
adequacy of the stabilizer’s protection against 
coalescence, and the low interfacial tension between 
aqueous and organic phases, resulting from their 
partially water-soluble nature [55]. Furthermore, 
comparing samples where the drug is absent and does 
not influence the size of the nanoparticles (Table 3; 
samples PLGA-NP1 and PLGA-NP3); the only factor 
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that justifies the difference in the obtained size is the 
type of stabilizer used. Hence, it is evident that when 
Pluronic F-68 was used, the nanoparticles obtained 
where significantly smaller (? 98 nm) than the 
nanoparticles obtained with PVA (? 129 nm). This 
indicates that Pluronic F68 is more adequate as a 
stabilizer of PLGA-NP conferring higher protection 
against coalescence of the particles. 
Besides the analysis of the size of the nanoparticles 
it is also important to analyze the polydispersity. The 
polydispersity values obtained for all the PLGA 
formulations were reasonably small (0.08-0.29) 
suggesting a fairly narrow and monomodal particle size 
distribution. 
Regarding the effect of the NSAID tested on the 
size of PLGA-NP, it is possible to conclude that the 
nanoparticles did not suffer large variations after the 
encapsulation of drug (Figure 3; samples PLGA-NP2 
and PLGA-NP4). This indicates that indomethacin is 
possibly homogeneously distributed and incorporated 
in the matrix of the nanoparticles, and thus, does not 
have a great influence on the size of the particles. 
Probably if the distribution of the drug was by 
adsorption at the surface of the nanoparticles, the 
effect on the size would be more evident. In close 
agreement to these results, other reported studies 
indicated that indomethacin was dissolved within the 
PLGA matrix and that no clear relationship could be 
established between particle size and the amount of 
drug loaded in the PLGA nanoparticles [12, 15, 55]. 
The zeta-potential of PLGA nanoparticles was 
negative because of the carboxyl end groups on PLGA 
and ranged between -15 to -24 mV (Figure 4). At a first 
approach one would think that the values obtained 
were not indicative of stable formulations, since it is 
generally assumed that, the most stable nanoparticles 
are the ones that present greater absolute values of 
zeta potential (?30 mV), which are correspondent to 
charged nanoparticles that will be stabilized by the 
multiple repulsion effects. However, this rule cannot be 
strictly applied to systems containing steric stabilizers, 
since their adsorption decreases the absolute value of 
zeta potential due to a shift in the shear plane of the 
particle [56]. Indeed, steric stabilizer polymers such as 
PVA and Pluronic F-68 may reduce the surface charge 
of the nanoparticles, but still keep the formulation 
stable by creating a shield between the nanoparticle 
surface and the surrounding medium, thereby 
protecting the nanoparticles from aggregation [57]. 
Moreover, it has been reported that highly negative 
zeta potential values in the range of -15 to -30 mV 
maintains nanoparticles stability [58]. Hence, the 
 
Figure 3: Average size (nm) represented as bars and 
polydispersity index represented as scatter points of the 
nanoparticles: PLGA-NP1 (PLGA nanoparticles containing 
PVA and unloaded); PLGA-NP2 (PLGA nanoparticles 
containing PVA and loaded with indomethacin); PLGA-NP3 
(PLGA nanoparticles containing Pluronic F68 and unloaded); 
PLGA-NP4 (PLGA nanoparticles containing Pluronic F68 and 
loaded with indomethacin); NLC1 (nanostructured lipid 
carriers unloaded); NLC2 (nanostructured lipid carriers 
loaded with indomethacin); NLC3 (chitosan coated 
nanostructured lipid carriers unloaded); NLC4 (chitosan 
coated nanostructured lipid carriers loaded with 
indomethacin). Patterned bars represent formulations loaded 
with indomethacin. Values are means ± standard deviations 
(n=4). 
 
 
Figure 4: Average zeta-potential (mV) represented as bars of 
the nanoparticles: PLGA-NP1 (PLGA nanoparticles 
containing PVA and unloaded); PLGA-NP2 (PLGA 
nanoparticles containing PVA and loaded with indomethacin); 
PLGA-NP3 (PLGA nanoparticles containing Pluronic F68 and 
unloaded); PLGA-NP2 (PLGA nanoparticles containing 
Pluronic F68 and loaded with indomethacin); NLC1 
(nanostructured lipid carriers unloaded); NLC2 
(nanostructured lipid carriers loaded with indomethacin); 
NLC3 (chitosan coated nanostructured lipid carriers 
unloaded); NLC4 (chitosan coated nanostructured lipid 
carriers loaded with indomethacin). Patterned bars represent 
formulations loaded with indomethacin. Values are means ± 
standard deviations (n=4). 
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developed formulations have good stability since the 
presented zeta potential values are within the same 
highly negative range.  
Comparing the effect of the two stabilizers used, the 
zeta potential of PLGA-Pluronic nanoparticles (-24.20 ± 
0.35) is higher in absolute values relatively to PLGA-
PVA nanoparticles (-14.54 ± 0.63). Despite of being 
considered a non-ionic polymer, PVA macromolecule 
contains some acetate groups that result from 
incomplete hydrolyses of polyvinyl acetate in the 
production process of PVA. The ionization of these 
acetate groups in the PVA macromolecule confers 
them negative charge [59], which explains the negative 
zeta-potential values obtained for PLGA-PVA 
nanoparticles. Pluronic F68 is also a non-ionic polymer 
but due to its lower molecular weight, only a partial 
screening of PLGA charges is caused by its adsorption 
to the nanoparticles surface, resulting in a nanoparticle 
with negative charge [60]. The lower absolute values of 
PLGA-PVA nanoparticles are the outcome of PVAs 
higher molecular weight which results in a higher 
screening of PLGA charges [60]. The higher absolute 
values of zeta potential observed for PLGA-Pluronic 
nanoparticles can be once more an indication of the 
greater stability of the nanoparticles with Pluronic F-68 
as emulsion stabilizer, which is in agreement to what 
has been said regarding the size of the nanoparticles. 
Regardless the type of stabilizer used (Pluronic F-
68 or PVA), indomethacin had also a stabilizing effect 
upon encapsulation into the nanoparticles, and 
although this effect was not very much pronounced 
(Figure 4; samples PLGA-NP2 and PLGA-NP4) it can 
be attributed to the fact of this drug being negatively 
charged at the pH of the studies (pKa of indomethacin 
= 4.5 [61]). 
In the case of the NLC, the average size order 
determined was higher for the formulations containing 
CS (Figure 3, samples NLC3 and NLC4). Indeed, it has 
been reported that CS coated nanoparticles present 
increased particle sizes which can be attributed to the 
amount of adsorbed CS on the surface of the 
nanoparticles [62, 63]. Besides the size of the 
nanoparticles, the adsorption of CS was further 
supported by the zeta-potential determinations (Figure 
4, samples NLC3 and NLC4). In fact, the positive zeta-
potential of CS coated NLC confirmed the presence of 
CS adsorbed to the nanoparticles surface, since that 
upon dissolution, the amine groups of CS are 
protonated and the resultant polymer is positively 
charged [64]. Despite the stabilizer used polysorbate 
60 being non-ionic the zeta potentials of NLC 
formulations without CS are negative (Figure 4, 
samples NLC1 and NLC2). Reported studies with 
nonionic ethoxylated surfactants show that they are 
negatively charged at pH > 3. The negative charge 
increases upon pH (that is, upon increasing bulk HO- 
concentration) [65, 66]. 
Regardless the type of NLC prepared (uncoated or 
coated with CS) indomethacin had also a stabilizing 
effect upon encapsulation into the nanoparticles. 
Indeed, in the case of uncoated NLC, the zeta potential 
values were more negative in the nanoparticles where 
the drug was added (Figure 4, sample NLC2). Similarly 
to PLGA-NP, the effect of indomethacin reducing the 
zeta potential, and thus the surface charge of the NLC 
must be related with the fact of this NSAID being 
negatively charged at the pH of the studies [61]. The 
adsorption of negatively charged indomethacin to the 
NLC surface might be also responsible for a higher 
amount of adsorbed CS that forms stable NLC with 
highly positive zeta potential values (Figure 4, sample 
NLC4). 
3.2. Encapsulation efficiency and loading efficiency 
of drug 
The encapsulation efficiencies (EE) and loading 
efficiencies (LE) of indomethacin were high either in 
PLGA-NP or NLC. EE and LE narrowly ranged 
between 87.58 ± 2.55 % - 98.87 ± 0.15 % and 3.38 ± 
0.18 % – 3.53 ± 0.12 % respectively (Figure 5). 
 
Figure 5: Average encapsulation efficiency (%) represented 
as bars and drug loading efficiency (%) represented as 
scatter points of indomethacin into the nanoparticles: PLGA-
NP2 (PLGA nanoparticles containing PVA and loaded with 
indomethacin); PLGA-NP4 (PLGA nanoparticles containing 
Pluronic F68 and loaded with indomethacin); NLC2 
(nanostructured lipid carriers loaded with indomethacin); 
NLC4 (chitosan coated nanostructured lipid carriers loaded 
with indomethacin). Values are means ± standard deviations 
(n=3). 
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In the case of PLGA-NP the encapsulation 
efficiency of indomethacin, did not improve much with 
the change of emulsion stabilizer. Indeed, for 
(PLGA+PVA) nanoparticles (PLGA-NP2) the EE was 
found to be 87.58±2.55 %, whereas for 
(PLGA+Pluronic F-68) nanoparticles (PLGA-NP4) the 
EE was determined to be 88.67±1.21 %. The 
percentages of indomethacin loaded into PLGA 
nanoparticles were above 85%, which means that, a 
large quantity of drug was incorporated, regardless the 
emulsion stabilizer used. Hence, the emulsion stabilizer 
does not seem relevant for the amount of drug loaded 
into the nanoparticles. This may happen because the 
drug is initially co-dissolved with PLGA and thus the 
amount of drug incorporated into the nanoparticles is 
more dependent on the core polymer than on the 
surface stabilizers. Moreover, it has been reported that 
hydrophilic drugs demonstrate lower affinity to the 
PLGA polymer, and tend to diffuse from the organic 
phase (where the polymer is dissolved) to the external 
aqueous medium during the spontaneous 
emulsification process of the polymer, leading to an 
unsatisfactory loading efficiency [12]. This must not be 
the case of indomethacin. In fact, the higher lipophilic 
character of indomethacin has been proved by means 
of partition coefficient determination between water and 
lipid media [67]. As a consequence, the higher 
lipophilic behavior of indomethacin assures that the 
interactions with the polymer are high in the organic 
phase and thus more drug remains encapsulated 
during the emulsification process.  
The values obtained for indomethacin incorporation 
efficiency in the NLC were even higher (about 99%) 
than in the PLGA nanoparticles, which confirms that a 
very large percentage of the drug is effectively 
distributed into the lipids that take part of the NLC 
composition, whether the particles are uncoated or 
coated with CS. The encapsulation of indomethacin 
was also not affected by the CS coating surface added 
to the NLC (Figure 5). In fact, NLC without CS (NLC2) 
have shown an EE of 98.87±0.15 %, whereas CS 
coated NLC (NLC4) present an EE of 97.69±0.08 %. In 
agreement, other studies have reported unaltered 
incorporation efficiency of drugs in NLC coated with CS 
or CS derivatives [43, 63]. 
3.3. Morphology of the Nanoparticles 
SEM microphotographs of PLGA-NP and NLC are 
shown in Figure 6 as typical examples.  
SEM analysis of the formulations allows the 
evaluation of the morphology of the nanoparticles. All 
PLGA-NP unloaded (Figure 6 PLGA-NP1 and PLGA-
NP3) or loaded with indomethacin (data not shown) 
exhibit a spherical shape and a smooth surface 
independently of their composition. The sizes of the 
nanoparticles observed by SEM have shown to be 
larger than the analyzed by DLS, however in 
agreement to DLS results; considering PLGA-NP 
(Figure 6), bigger sizes were obtained when PVA was 
used as emulsion stabilizer (Figure 6 PLGA-NP1) and 
the sizes are more homogeneous (around 200 nm). 
Contrastingly the PLGA nanoparticles obtained with 
Pluronic F68 (Figure 6 PLGA-NP3) are smaller and 
reveal a wider size distribution (sizes range between 85 
nm till 200 nm) which is in agreement with the larger 
polydispersity values found in the measurements of 
DLS. In agreement with DLS, SEM images of uncoated 
NLC (Figure 6 NLC1) show the smallest sizes 
(between 85 till 100 nm) however these nanoparticles 
are not perfectly spherical but more deformed and 
elongated. The shape changes were even more 
evident in CS coated NLC for which ‘platelet-like‘ or 
 
Figure 6: SEM microphotographs of unloaded nanoparticles: (PLGA-NP1) PLGA nanoparticles prepared with PVA as stabilizer; 
(PLGA-NP3) PLGA nanoparticles prepared with Pluronic F68 as stabilizer; (NLC1) Lipid nanoparticles without chitosan; (NLC3) 
Lipid nanoparticles coated with chitosan. A = 85 nm; B = 100 nm; C = 200 nm. 
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‘needle’-like structures are observed (Figure 6 NLC3). 
A probable explanation to this is related to the fact that 
SEM analysis was not performed immediately after 
nanoparticles production, but after one month of 
storage. During storage the NLC coated with CS might 
have suffered a transition from the less stable 
crystalline modifications (? state) towards the more 
stable ? form occurs [68, 69]. This leads to formation of 
more ordered and stable crystalline structures in the 
lipids. Moreover, the transformation to more ordered 
crystalline structures causes a shape change from 
spherical to platelet-like or needle-like. The shape 
transformation results in increase in the overall surface 
area. These assumptions are further supported by DSC 
analysis of the lipid NP where CS coated NLC have 
shown higher interferences with lipid crystallization. 
The difference of sizes of the nanoparticles 
according to the measurement technique (DLS and 
SEM) can be due to the inherent differences of both 
techniques and also to the possible sample 
deformation caused by the drying process of the 
aqueous media and/or by the effect of the highly 
energetic electron beam. This latter effect may also 
contribute for the non-spherical shapes observed. 
Future Cryo-SEM and cryo-TEM measurements, more 
adequate for lipid nanoparticles evaluation will improve 
the characterization of the nanoparticles. Nevertheless, 
SEM already confirmed no disruptions of PLGA-NP 
spherical structure and integrity, even after application 
of various mechanical stresses such as sonication and 
ultra-homogenization. 
3.4. Physical State and Polymorphism of Lipid 
Nanoparticles  
The required final physical state of the NLC after 
production is the solid state. Though, a crystalline lipid 
(cetyl palmitate) was used in the production of NLC 
dispersions; the final physical state of the nanoparticles 
can be other than solid, due to the presence of the 
liquid lipid and to the well known supercooling effect. 
Supercooled melts (emulsions) are produced instead of 
nanoparticles dispersions when the melting point of the 
formulation is well below to the room temperature (e.g. 
trimyristin based lipid nanocarriers) [70, 71]. For that 
reason, determining the physical state of the lipid 
matrix is essential for the development of nanoparticles 
based on solid lipids. In the current study, solid state 
state of NLC was confirmed for both body (37 °C) and 
room temperatures (25 °C) since the melting peaks 
were well above these temperatures. The DSC results 
obtained for each type of NLC are depicted in Table 4.  
Thermal transitions in the DSC heating curve 
revealed that the NLC developed in this study were 
particles with crystalline lipids and revealed two distinct 
polymorphic modifications with two separate melting 
point peaks. The first peak with lower melting point was 
attributed to the ?-polymorphic form (metastable), 
whereas the second peak was attributed to the ?-
polymorphic form (stable form). Overall, the NLC’s 
melting points were lower than those obtained for the 
bulk materials, which can be attributed to the presence 
of surfactant and to the colloidal low dimensions of the 
particles, in particular to their high surface area to 
volume ratio. All these factors imply the creation of 
lattice defects onto the lipid matrices, following a 
decrease in their crystallinity in comparison to their bulk 
counterparts [71]. Indeed, the melting enthalpy in 
unloaded NLC decreased from 186 ± 0.110 J/g (bulk 
mixture) to 7.2 ± 0.83 J/g for the unloaded NLC without 
chitosan (NLC1) and to 2.9 ± 0.45 J/g for the unloaded 
NLC with chitosan (NLC3) (Table 4), indicating a 
slower recrystallization and a crystal order disturbance. 
Also, enthalpy of bulk mixtures decreased relatively to 
the corresponding solid lipid (Cetyl palmitate). This was 
expected to happen, since Miglyol-812 (liquid lipid) 
Table 4: Experimental Data Obtained from DSC Analysis of the NLC Formulations. Values Reported are the Mean 
Diameter ± Standard Deviation for at least 3 Determinations 
Formulations ?H (J/g)* Lower melting point (°C) ? - form 
Higher melting point (°C) 
? - form RI (%) 
NLC1 7.2 ± 0.83 46.0 ± 0.380 50.5 ± 0.580 77.0 
NLC2 6.5 ± 0.92 43.0 ± 0.395 50.1 ± 0.581 70.1 
NLC3 2.9 ± 0.45 - 50.0 ± 0.622 61.7 
NLC4 2.6 ± 0.11 - 49.6 ± 0.743 56.3 
Bulk lipids 186 ± 0.110 46.3 ± 0.580 54.9± 0.610 100 
Cetyl palmitate 267 ± 0.180 47.5 ± 0.420 56.9± 0.324 - 
*Obtained from the higher melting point. 
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incorporation induces the formation of lower energy 
lipid forms and thus lowers the crystallization and 
melting temperatures of the particle matrix and 
accelerates the transition of the solid lipid into the 
stable ?-polymorph after crystallization. Additionally, 
CS and surfactants distributed in the melted lipid phase 
can interfere with lipid crystallization, resulting in a 
lower melting enthalpy (Table 4). According to that, the 
RI was lower in the presence of CS (56 % – 62 %) than 
in its absence (70 % - 77 %). Furthermore, the 
presence of guest molecules in the lipid matrix normally 
influences its crystallization degree, decreasing the 
lipid layer organization. Thus, it is understandable that 
the melting point and enthalpy values were slightly 
lower in drug-loaded NLC (NLC2 and NLC4) which 
translates in lower RI values (Table 4). This indicates 
that the drug reduces the cooperativity of the phase 
transition reducing also the lipid packing. All NLC 
loaded formulations presented a single maximum peak 
(higher melting point) which constitutes an indication 
that indomethacin was not in crystalline state but rather 
completely entrapped within the nanoparticles due to 
the rapid ordering of drug within the lipid matrix upon 
nanoparticles preparation. Similar results were reported 
stating that rapid ordering of the microemulsion does 
not allow the drug to crystallize [72]. Despite the 
enthalpy obtained for the bulk lipids being much higher 
than that of NLCs, meaning that there is a loss of 
crystallinity of the lipids after their incorporation into 
NLCs, the lipids in these formulations still possess a 
high degree of crystallinity, as observed by the 
presence of ?-form melting point and by the fact that 
the recrystallization index (RI) range of the NLC was 
always above 50 % (56 - 77%) (Table 4). The 
thermogram parameters of the NLC uncoated and 
coated with CS (Table 4) were quite similar and 
revealed a ?-endotherm at 49.6-50.5 °C. This similarity 
is due to the fact that both the melting and 
crystallization properties of the NLC were mainly 
governed by the hard fat component [73]. However 
being similar, uncoated NLC show a shoulder 
corresponding to the ?-form, meaning that some of the 
lipid matrix is crystallized in a lower energy lipid form. 
The ?-form was not visible in the CS coated NLC 
suggesting that polymorphic transitions can occur more 
rapidly in coated NLC than in uncoated ones. As a 
general rule the stable modifications of the lipids 
usually exhibit lower EE. For that reason, drug 
expulsion may occur after transitions of the lipid 
crystalline structure in the CS coated NLC, possibly by 
the dislocation of the drug from the lipid core to the 
polymeric shell.  
3.5. Drug Release Studies 
The percentage of drug released was calculated by 
dividing the cumulative amount of drug released at a 
given time by the amount of total drug present in 5.0 g 
of nanoparticles. Release studies at 24 h indicated 
higher indomethacin release from CS coated NLC 
(75.61% ± 12.25) followed by indomethacin release 
from uncoated NLC (64.38% ± 8.50) and the slower 
release was observed for PLGA-NP with very similar 
release (60.00 ± 8.10 for PLGA-NP2 and 58.20 ± 9.10 
for PLGA-NP4).  
The release rates from lipid nanoparticles can be 
considered as mediated by several partition 
mechanisms between the aqueous medium 
surrounding the nanoparticles, the surfactant employed 
and the lipid phases [14]. One has to also consider that 
according to DSC analysis both chitosan and 
indomethacin significantly change the NLC lipid order, 
promoting more fluid systems from which the release of 
contents is facilitated.  
The polymeric nanospheres produced within this 
work have been described to present a spherical matrix 
structure in which the pharmaceutical drug can be 
absorbed on the surface, or physically and uniformly 
dispersed within the matrix [74]. Furthermore, the 
release of drugs from PLGA matrix was shown to be 
biphasic, initially mainly by drug diffusion through the 
polymer matrix and later through both diffusion of the 
therapeutic agent and the degradation of the polymer 
matrix itself [75]. Finally, it has been reported that the 
drug(s) having amino functional groups such as amines 
(which is the case of indomethacin) have the potential 
to interact with polymer pendant groups, accelerating 
the polymer degradation rates and the release rates of 
the drugs incorporated in the polyester matrix [76]. 
These 3 aspects combined justify the initial burst of 
approximately 60% release of drug in 24 h even though 
the polymeric matrix has been described to promote 
much more prolonged releases. Nevertheless, 
indomethacin used in classical formulations 
(commercial pharmaceutical formulations) is released 
from formulation reaching plasma peak concentrations 
in 2 h [77] which is a fast release of 100% of drug 
administrated and not comparable with the 60% 
release that we have reached with polymeric 
nanoparticles in 24 h. Furthermore, gastric digestion 
takes about 4 hours, and the presence of NSAIDs 
during this period in stomach has several deleterious 
consequences. The nanoparticles presented in this 
study released negligible quantities of drug in the time 
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length of gastric digestion (4 h) and released 60% of 
drug in 24h. Therefore this is a good indication for less 
gastric toxicity. 
CONCLUSIONS 
PLGA and lipid nanoparticles encapsulating 
indomethacin were successfully prepared and 
characterized. This study confirms that both polymeric 
and lipid nanoparticles are suitable for the preparation 
of NSAID containing carriers with high encapsulation 
efficiency and drug releasing rates. Accordingly, both 
types of formulations can be used to improve the 
therapeutic efficacy of the tested drug and reduce their 
GI effects by the protection conferred by either the 
polymeric or the lipidic matrix.  
In the case of PLGA-NP, both nanoparticle size and 
stability were affected by changing the type of stabilizer 
used. In this context, Pluronic F-68 has been 
responsible for smaller and more stable nanoparticles. 
Contrastingly drug loading into the nanoparticles 
revealed to be independent from the type of stabilizer 
and dependent of the lipophilicity of the drug. 
Indomethacin, is highly lipophilic, and as such, does 
not suffer from the problems of leakage of drug to the 
external medium, resulting in improved drug content in 
the nanoparticles. In any case, no clear relationship 
has been established between particle size and the 
amount of drug loaded in the PLGA nanoparticles.  
In the case of NLC, both nanoparticle size and 
stability were affected by coating the nanoparticles with 
CS. In this context, CS coating has been responsible 
for bigger but still more stable nanoparticles, since the 
highly positive charge density of the nanoparticles’ 
surface, conferred by adsorbed CS, will keep the 
repulsions between the NLC and avoid aggregation. 
Similarly, drug loading into the nanoparticles revealed 
to be improved by the CS coating. Hence, the NLC 
coated with CS revealed to be very promising causing 
improved stability and high drug release and besides 
that, the CS coated nanoparticles might also favor the 
interaction with mucosa epithelia and favor adhesion in 
vivo. 
Before concluding about the real potentiality of 
these nanoformulations and the possibility of actually 
using these nanoparticles in therapy, several 
experiments still need to be performed, like for example 
drug release studies from the nanoparticles at 
inflammatory pH and cellular uptake of the drug. 
Nevertheless, this study contributed to confirm that the 
nanoparticles tested, particularly nanoparticles coated 
with CS are a progress beyond the state-of-art showing 
high drug loading efficiency and drug formulation 
stability advantages and thus showing potentiality to be 
applied as NSAID nanocarriers improving the use of 
these drugs in inflammation treatments. 
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